Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 10, 2026 20:15 UTC |
Oyegunwa AkinboladeEVP, CIO & CTO
|
Tax withholdingCommon Stock | 51 | $274.01 | $13,974.51 |
DisclosureSEC source: 0000920148-26-000032 · form4.xml · nonDerivative · entry 4 Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,944.253 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:13 UTC |
Schechter Adam HDirector · President & CEO
|
Tax withholdingCommon Stock | 1,352 | $274.01 | $370,461.52 |
DisclosureSEC source: 0000920148-26-000031 · form4.xml · nonDerivative · entry 4 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,616 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:08 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 46 | $274.01 | $12,604.46 |
DisclosureSEC source: 0000920148-26-000030 · form4.xml · nonDerivative · entry 4 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,028.2194 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:07 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Tax withholdingCommon Stock | 53 | $274.01 | $14,522.53 |
DisclosureSEC source: 0000920148-26-000029 · form4.xml · nonDerivative · entry 6 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,926.1426 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:07 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Tax withholdingCommon Stock | 166 | $274.01 | $45,485.66 |
DisclosureSEC source: 0000920148-26-000029 · form4.xml · nonDerivative · entry 5 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,979.1426 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:06 UTC |
van der Vaart Sandra DEVP, Corporate Affairs
|
Tax withholdingCommon Stock | 93 | $274.01 | $25,482.93 |
DisclosureSEC source: 0000920148-26-000028 · form4.xml · nonDerivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Corporate Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,849.4864 F3 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:05 UTC |
Vaughn Bryan TEVP, Diagnostics
|
Tax withholdingCommon Stock | 61 | $274.01 | $16,714.61 |
DisclosureSEC source: 0000920148-26-000027 · form4.xml · nonDerivative · entry 4 Vaughn Bryan T · CIK 0002103999 · EVP, Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,382.5702 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:04 UTC |
Meltzer Jonathan CEVP, Operations
|
Tax withholdingCommon Stock | 82 | $274.01 | $22,468.82 |
DisclosureSEC source: 0000920148-26-000026 · form4.xml · nonDerivative · entry 5 Meltzer Jonathan C · CIK 0002103998 · EVP, Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,787.3256 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:04 UTC |
Meltzer Jonathan CEVP, Operations
|
SaleCommon Stock | 88 | $275.53 | $24,246.64 |
DisclosureSEC source: 0000920148-26-000026 · form4.xml · nonDerivative · entry 4 Meltzer Jonathan C · CIK 0002103998 · EVP, Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,869.3256 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:02 UTC |
Kyle Kathryn WEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 61 | $274.01 | $16,714.61 |
DisclosureSEC source: 0000920148-26-000024 · form4.xml · nonDerivative · entry 4 Kyle Kathryn W · CIK 0002103996 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,288.4574 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:01 UTC |
GRAHAM ANITA ZEVP, CHRO
|
Tax withholdingCommon Stock | 112 | $274.01 | $30,689.12 |
DisclosureSEC source: 0000920148-26-000023 · form4.xml · nonDerivative · entry 4 GRAHAM ANITA Z · CIK 0001206814 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,213 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:00 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Tax withholdingCommon Stock | 80 | $274.01 | $21,920.80 |
DisclosureSEC source: 0000920148-26-000022 · form4.xml · nonDerivative · entry 4 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,574.5 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 19:58 UTC |
Bailey Megan D.EVP, Pres, Central Labs & Intl
|
Tax withholdingCommon Stock | 23 | $274.01 | $6,302.23 |
DisclosureSEC source: 0000920148-26-000021 · form4.xml · nonDerivative · entry 6 Bailey Megan D. · CIK 0001975682 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,883 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 19:58 UTC |
Bailey Megan D.EVP, Pres, Central Labs & Intl
|
Tax withholdingCommon Stock | 85 | $274.01 | $23,290.85 |
DisclosureSEC source: 0000920148-26-000021 · form4.xml · nonDerivative · entry 5 Bailey Megan D. · CIK 0001975682 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,906 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:18 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Exercise / conversionRestricted Stock Unit · Derivative | 111 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000033 · form4.xml · derivative · entry 9 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,890 Underlying: Common Stock · 111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F6 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:18 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Exercise / conversionRestricted Stock Unit · Derivative | 517 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000033 · form4.xml · derivative · entry 8 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,001 Underlying: Common Stock · 517 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F6 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:18 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Exercise / conversionCommon Stock | 111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000033 · form4.xml · nonDerivative · entry 4 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,257.9234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:18 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Exercise / conversionCommon Stock | 517 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000033 · form4.xml · nonDerivative · entry 3 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,146.9234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:15 UTC |
Oyegunwa AkinboladeEVP, CIO & CTO
|
Exercise / conversionRestricted Stock Unit · Derivative | 149 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000032 · form4.xml · derivative · entry 6 Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,610 Underlying: Common Stock · 149 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in two equal installments beginning on February 7, 2025 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in two equal installments beginning on February 7, 2025 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:15 UTC |
Oyegunwa AkinboladeEVP, CIO & CTO
|
Exercise / conversionCommon Stock | 149 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000032 · form4.xml · nonDerivative · entry 3 Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,995.253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:13 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,249 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000031 · form4.xml · derivative · entry 6 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,430 Underlying: Common Stock · 3,249 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:13 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionCommon Stock | 3,249 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000031 · form4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:08 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 134 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000030 · form4.xml · derivative · entry 6 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,224 Underlying: Common Stock · 134 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:08 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 134 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000030 · form4.xml · nonDerivative · entry 3 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,074.2194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:07 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Exercise / conversionRestricted Stock Unit · Derivative | 164 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000029 · form4.xml · derivative · entry 9 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,164 Underlying: Common Stock · 164 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:07 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Exercise / conversionRestricted Stock Unit · Derivative | 517 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000029 · form4.xml · derivative · entry 8 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,328 Underlying: Common Stock · 517 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:07 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Exercise / conversionCommon Stock | 164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000029 · form4.xml · nonDerivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,145.1426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:07 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Exercise / conversionCommon Stock | 517 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000029 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,981.1426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:06 UTC |
van der Vaart Sandra DEVP, Corporate Affairs
|
Exercise / conversionRestricted Stock Unit · Derivative | 353 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000028 · form4.xml · derivative · entry 6 van der Vaart Sandra D · CIK 0001537208 · EVP, Corporate Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,517 Underlying: Common Stock · 353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F6 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:06 UTC |
van der Vaart Sandra DEVP, Corporate Affairs
|
Exercise / conversionCommon Stock | 353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000028 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Corporate Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,942.4864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:05 UTC |
Vaughn Bryan TEVP, Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 178 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000027 · form4.xml · derivative · entry 6 Vaughn Bryan T · CIK 0002103999 · EVP, Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,624 Underlying: Common Stock · 178 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested on February 7, 2026. F5 · derivative.expiration_date: The Restricted Stock Units vested on February 7, 2026. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:05 UTC |
Vaughn Bryan TEVP, Diagnostics
|
Exercise / conversionCommon Stock | 178 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000027 · form4.xml · nonDerivative · entry 3 Vaughn Bryan T · CIK 0002103999 · EVP, Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,443.5702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:04 UTC |
Meltzer Jonathan CEVP, Operations
|
Exercise / conversionRestricted Stock Unit · Derivative | 263 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000026 · form4.xml · derivative · entry 7 Meltzer Jonathan C · CIK 0002103998 · EVP, Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,317 Underlying: Common Stock · 263 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units vested on February 7, 2026. F6 · derivative.expiration_date: The Restricted Stock Units vested on February 7, 2026. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:04 UTC |
Meltzer Jonathan CEVP, Operations
|
Exercise / conversionCommon Stock | 263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000026 · form4.xml · nonDerivative · entry 3 Meltzer Jonathan C · CIK 0002103998 · EVP, Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,957.3256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:02 UTC |
Kyle Kathryn WEVP, Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 178 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000024 · form4.xml · derivative · entry 6 Kyle Kathryn W · CIK 0002103996 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,600 Underlying: Common Stock · 178 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested on February 7, 2026. F5 · derivative.expiration_date: The Restricted Stock Units vested on February 7, 2026. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:02 UTC |
Kyle Kathryn WEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 178 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000024 · form4.xml · nonDerivative · entry 3 Kyle Kathryn W · CIK 0002103996 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,349.4574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:01 UTC |
GRAHAM ANITA ZEVP, CHRO
|
Exercise / conversionRestricted Stock Unit · Derivative | 367 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000023 · form4.xml · derivative · entry 6 GRAHAM ANITA Z · CIK 0001206814 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,397 Underlying: Common Stock · 367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:01 UTC |
GRAHAM ANITA ZEVP, CHRO
|
Exercise / conversionCommon Stock | 367 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000023 · form4.xml · nonDerivative · entry 3 GRAHAM ANITA Z · CIK 0001206814 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:00 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 222 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000022 · form4.xml · derivative · entry 6 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 914 Underlying: Common Stock · 222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:00 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Exercise / conversionCommon Stock | 222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000022 · form4.xml · nonDerivative · entry 3 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,654.5 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 19:58 UTC |
Bailey Megan D.EVP, Pres, Central Labs & Intl
|
Exercise / conversionRestricted Stock Unit · Derivative | 67 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000021 · form4.xml · derivative · entry 9 Bailey Megan D. · CIK 0001975682 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,130 Underlying: Common Stock · 67 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 19:58 UTC |
Bailey Megan D.EVP, Pres, Central Labs & Intl
|
Exercise / conversionRestricted Stock Unit · Derivative | 222 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000021 · form4.xml · derivative · entry 8 Bailey Megan D. · CIK 0001975682 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,197 Underlying: Common Stock · 222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 19:58 UTC |
Bailey Megan D.EVP, Pres, Central Labs & Intl
|
Exercise / conversionCommon Stock | 67 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000021 · form4.xml · nonDerivative · entry 4 Bailey Megan D. · CIK 0001975682 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 19:58 UTC |
Bailey Megan D.EVP, Pres, Central Labs & Intl
|
Exercise / conversionCommon Stock | 222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000021 · form4.xml · nonDerivative · entry 3 Bailey Megan D. · CIK 0001975682 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:34 UTC |
Wang Julia AijunChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 893 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000036 · form4.xml · derivative · entry 3 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,474 Underlying: Common Stock · 893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:34 UTC |
Wang Julia AijunChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 254 | $277.20 | $70,408.80 |
DisclosureSEC source: 0000920148-26-000036 · form4.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,202.239 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:34 UTC |
Wang Julia AijunChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000036 · form4.xml · nonDerivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,456.239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:18 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Exercise / conversionRestricted Stock Unit · Derivative | 670 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000033 · form4.xml · derivative · entry 7 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,518 Underlying: Common Stock · 670 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:18 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Tax withholdingCommon Stock | 209 | $277.20 | $57,934.80 |
DisclosureSEC source: 0000920148-26-000033 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,629.9234 F3 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:18 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Exercise / conversionCommon Stock | 670 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000033 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,838.9234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · balance_after: Amount includes 57.1306 shares acquired on June 30, 2025 under the Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan and 45.1355 shares acquired on December 31, 2025 under the Labcorp Holdings Inc. 2025 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.